Trimetazidine and cardioprotection: facts and perspectives
- PMID: 24719262
- DOI: 10.1177/0003319714530040
Trimetazidine and cardioprotection: facts and perspectives
Abstract
Trimetazidine (TMZ) is a metabolic agent used in cardiology for more than 40 years. Several studies assessed the cardioprotective effects of TMZ in patients with chronic coronary heart disease (CHD) as well as in patients with heart failure (HF). In light of the inclusion of TMZ in the current guidelines on the management of stable CHD, we reviewed the published literature on TMZ, focusing mainly its effects on patients with stable angina and HF. According to the published literature, there is sufficient evidence to support the addition of this agent in the treatment of symptomatic patients with stable angina.
Keywords: coronary heart disease; heart failures; stable angina; trimetazidine.
© The Author(s) 2014.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources